Education
About Us
Working with TipRanks
Follow Us
Hcw Biologics, Inc. (HCWB)
:HCWB
HCWB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.00 - $100.80
Previous CloseN/A
Volume102.01K
Average Volume (3M)1.35M
Market Cap
$17.66M
Enterprise ValueN/A
Total Cash (Recent Filing)$998.22K
Total Debt (Recent Filing)$12.80M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Aug 08, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.00
Shares Outstanding2,110,359
10 Day Avg. Volume4,005,172
30 Day Avg. Volume1,351,421
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)-1.14
Price to Sales (P/S)0.00
P/FCF Ratio-0.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.00Price Target Upside-64.16% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering0
HCW Biologics News
PremiumCompany Announcements
HCW Biologics Issues Shares Through Warrant Exercise
PremiumCompany Announcements
HCW Biologics Enters Securities Purchase Agreement
PremiumCompany Announcements
HCW Biologics Closes $5 Million Public OfferingBulls Say, Bears Say
Bulls Say
Capital And FundingThe company raised $6.9M from a registered direct offering, providing operational breathing room and allowing pipeline advancement.
Clinical TrialsHCW Biologics announced the clearance of HCW9302 to enter a Phase 1 clinical trial in patients with moderate to severe alopecia areata.
New Discovery PlatformA $7M upfront deal validates the potential of HCW Biologics' new discovery platform for multifunctional cytokines.
Bears Say
Financial PerformanceHCW Biologics reported a net loss and, despite recent capital influx, further capital will be required due to remaining legal expenses.
Legal And Financial ObligationsDespite recent capital influx, HCW Biologics has remaining legal expenses of $14.4M and may require further capital.
Options Prices
Currently, No data available
---
Ownership Overview
41.36%
Insiders
5.03% Mutual Funds
5.45% Other Institutional Investors
53.13% Public Companies and Individual Investors
HCWB FAQ
What was Hcw Biologics, Inc.’s price range in the past 12 months?
Hcw Biologics, Inc. lowest stock price was $5.00 and its highest was $100.80 in the past 12 months.
What is Hcw Biologics, Inc.’s market cap?
Hcw Biologics, Inc.’s market cap is $17.66M.
When is Hcw Biologics, Inc.’s upcoming earnings report date?
Hcw Biologics, Inc.’s upcoming earnings report date is Aug 08, 2025 which is in 72 days.
How were Hcw Biologics, Inc.’s earnings last quarter?
Hcw Biologics, Inc. released its earnings results on May 15, 2025. The company reported -$2 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.
Is Hcw Biologics, Inc. overvalued?
According to Wall Street analysts Hcw Biologics, Inc.’s price is currently Overvalued.
Does Hcw Biologics, Inc. pay dividends?
Hcw Biologics, Inc. does not currently pay dividends.
What is Hcw Biologics, Inc.’s EPS estimate?
Hcw Biologics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hcw Biologics, Inc. have?
Hcw Biologics, Inc. has 2,110,359 shares outstanding.
What happened to Hcw Biologics, Inc.’s price movement after its last earnings report?
Hcw Biologics, Inc. reported an EPS of -$2 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 9.146%.
Which hedge fund is a major shareholder of Hcw Biologics, Inc.?
Currently, no hedge funds are holding shares in HCWB
HCW Biologics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (-64.16% Downside)
$3.00 (-64.16% Downside)
Insider Transactions
Bought Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 29.1%
Last 30 Days ▲ 29.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.97%
12-Months-Change
Fundamentals
Return on Equity
-9999.00%
Trailing 12-Months
Asset Growth
-13.61%
Trailing 12-Months
Company Description
Hcw Biologics, Inc.
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
HCWB Stock 12 Month Forecast
Average Price Target
$3.00
▼(-64.16%Downside)
Technical Analysis
Carisma Therapeutics
―
PharmaCyte Biotech
―
Aprea Therapeutics
―
Dogwood Therapeutics
―
Turnstone Biologics Corp.
―